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Enalapril is a recently developed angiotensin-converting 
enzyme inhibitor that improves cardiac function at rest 
in patients with congestive heart failure. This study in-
vestigated the acute effects of enalapril on the cardio-
vascular response to exercise, and then evaluated the 
long-term effects of enalapril on exercise capacity and 
functional status during a 12 week placebo-controlled 
trial in patients with heart failure. Ten patients under-
went hemodynamic monitoring while at rest and during 
incremental bicycle exercise before and after 5 to 10 mg 
of enalapril orally. At rest, enalapril decreased mean 
blood pressure 13% (p < 0.01) and systemic vascular 
resistance 20% (p < 0.05) and increased stroke volume 
index 21 % (p < 0.01). During maximal exercise, ena-
lapril decreased systemic vascular resistance and in-
creased both cardiac and stroke volume indexes. Ena-
lapril acutely increased exercise duration (p < 0.05) and 
There is a consensus that the renin-angiotensin system con-
tributes to systemic vasoconstriction in patients with conges-
tive heart failure. Both competitive antagonism of angio-
tensin II by saralasin and inhibition of the angiotensin-con-
verting enzyme by teprotide and captopril result in vaso-
dilation and improvement in cardiac function at rest (1-8). 
A beneficial hemodynamic response to exercise has also 
been observed after captopril administration (9,10). The 
clinical efficacy of captopril, in particular, has been dem-
onstrated in placebo-controlled trials (10, II). Occasionally, 
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maximal oxygen consumption (p < 0.001). 
These 10 patients and an additional 13 patients were 
then randomized to either placebo or enalapril treatment 
and followed up for 12 weeks. Of the 11 patients assigned 
to active treatment, 73% considered themselves im-
proved compared with 25 % of the patients assigned to 
placebo treatment (p < 0.02). During long-term treat-
ment, exercise capacity increased in patients receiving 
enalapril (p < 0.001) but was unchanged in patients 
receiving placebo (intergroup difference, p < 0.05). Dur-
ing long-term treatment, no adverse effects of enalapril 
occurred. Thus, enalapril improves cardiac function at 
rest and during exercise. Compared with placebo, main-
tenance therapy with enalapril results in symptomatic 
improvement and increased exercise capacity. 
(J Am Coli CardioI1985;6:163-70) 
side effects such as dysgeusia, skin rash and blood dyscra-
sias prohibit the use of captopril in patients who would 
otherwise benefit from angiotensin blockade. Furthermore, 
the three times daily dosage schedule typically used in the 
treatment of heart failure may adversely affect patient 
compliance. 
Enalapril, a recently developed synthetic tripeptide an-
giotensin-converting enzyme inhibitor with a comparatively 
long duration of action, has proven effective in patients with 
hypertension (12,13). In patients with congestive heart fail-
ure, it has been shown to improve cardiac function at rest 
(14,15). Hemodynamic and clinical improvement is sus-
tained for at least 1 month (14,15). 
The effect of this drug on exercise hemodynamics has 
not been reported. Since patients with congestive heart fail-
ure are primarily symptomatic with effort, adequate as-
sessment of a therapeutic intervention should include an 
evaluation of cardiac performance during submaximal and 
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maximal exercise. Furthermore, evaluation of the long-term 
clinical efficacy of enalapril requires a placebo-controlled 
trial. Accordingly, this investigation was undertaken to as-
sess the acute effect of enalapril on exercise hemodynamics, 
exercise duration and maximal oxygen consumption in pa-
tients with heart failure. In addition, a 12 week placebo-
controlled study was conducted to assess the chronic effect 
of enalapril on symptoms, exercise duration and noninvasive 
indexes of cardiac function. 
Methods 
Study patients. Twenty-three men with symptoms and 
signs of severe congestive heart failure participated in this 
investigation. The mean (± SD) age of the patients was 57 
± 11 years (range 31 to 71). The cause of congestive heart 
failure was coronary artery disease in 12 patients as docu-
mented by prior myocardial infarction or coronary angi-
ography, or both. Three patients had a history of hyperten-
sion, although none had a blood pressure greater than 140/90 
mm Hg at the time of enrollment. Six patients had a primary 
cardiomyopathy of unknown origin. Two patients had se-
vere left ventricular dysfunction as a consequence of end-
stage valvular heart disease. Patients who had had a myo-
cardial infarction within 3 months were excluded. The 
duration of heart failure averaged 2.1 ± 2.4 years (range 
3 months to 10 years). Seven patients were categorized in 
New York Heart Association functional class II and 16 in 
class III. All had been receiving digitalis and diuretic drugs. 
The protocols employed had the approval of the appropriate 
Institutional ~eview Board for Human Research. 
Experimental Design 
The experimental protocol was divided into three phases: 
1) a baseline evaluation phase lasting 7 to 14 days; 2) an 
open-label dose titration phase lasting 2 to 3 days during 
whiCh the acute hemodynamic studies were conducted; and 
3) a randomized, double-blind parallel design, placebo-con-
trolled phase lasting 12 weeks. 
Baseline phase. Initially, all patients underwent a com-
plete clinical evaluation. The clinical status and treatment 
were maintained at a constant level throughout this phase. 
Functional status was assessed and graded using a ques-
tionnaire and classification system described by Feinstein 
and Weils (16). The questionnaire enabled the investigators 
to apply a numerical score based on the patient's perception 
of functional impairment and exercise capacity. Clinical 
assessment of improvement or deterioration throughout the 
study was compared with the baseline evaluation. In ad-
dition, patients were assigned to a functional classification 
by the investigating physician. 
At least two treadmill exercise tests were performed using 
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a modified Naughton protocol in which the exercise load 
was increased progressively in 2 minute stages (17). To 
qualify, the patient's exercise capacity had to exceed stage 
III (4 minutes) but be less than stage IX (16 minutes) of 
this protocol. Furthermore, the durations of exercise were 
required to be within 10% of each other for two successive 
tests. Exercise was terminated when the patient was unable 
to continue because of dyspnea or fatigue. No patient was 
limited by angina, claudication, arrhythmia or hypotension. 
A radionuclide equilibrium blood pool ventriculogram for 
assessment of left ventricular ejection fraction was also per-
formed. The details of this technique have been previously 
described (18). 
Open-label dose titration. Ten of the patients partici-
pated in an acute invasive hemodynamic assessment of en-
alapril. The remaining 13 patients were monitored nonin-
vasively (blood pressure and heart rate) during hospitalization. 
Patients were maintained on an 86 mEq sodium diet daily 
for at least 3 days before study. Vasodilator medications 
were discontinued at least 48 hours before the investigation. 
Digitalis, diuretic drugs and all medications other than an-
tiarrhythmic agents were withheld on the morning of the 
hemodynamic study but were given in the afternoon after 
hemodynamic measurements were completed. 
Acute hemodynamic protocol. On the evening before the 
study, each of the 10 participating patients underwent right 
heart catheterization with a Swan-Ganz catheter (Edwards 
Laboratories) and radial artery cannulation. Heart rate was 
determined from the simultaneous electrocardiographic sig-
nal. Cardiac output was determined by thermodilution av-
eraging three successive measurements varying by less than 
10%. Hemodynamic indexes were calculated from pressure 
and output values according to standard formulas (19). 
Respiratory gas analysis and determination of cardiac 
output. A Beckman metabolic cart comprising a volume 
transducer, a Beckman OM-II oxygen analyzer and a Beck-
man UB-2 carbon dioxide analyzer was used to determine 
minute volume oxygen consumption (V02) , and minute vol-
ume carbon dioxide (VC02) production (STPD). Blood was 
collected for arterial and mixed venous oxygen content and 
analyzed on a Lex-OrCon oxygen analyzer (Lexington In-
struments). The Fick cardiac output was calculated as the 
ratio of the V02 to the arterial-venous oxygen content 
difference. 
Measurement of plasma renin activity. Samples of mixed 
venous blood for plasma renin activity were collected while 
the patients were supine and after 15 minutes of upright 
posture, and at peak exercise before and after enalapril 
administration. The specimens were immediately placed on 
ice and centrifuged at 4°C. Plasma renin activity was de-
termined by a radioimmunoassay (20). 
Exercise protocol. Patients were studied in the postab-
sorptive state without premedication. Hemodynamic mea-
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surements were made while patients were seated on a Mon-
arch upright bicycle ergometer. Upright systemic 
hemodynamic data were collected until three successive de-
terminations 10 minutes apart demonstrated homeostasis. 
Simultaneous respiratory gas analysis also confirmed a sta-
ble rest state. Patients then began exercise at incremental 
work loads of 150 kp. m. The duration of each stage was 
3 minutes. Hemodynamic measurements, collection of ar-
terial and mixed venous blood for oxygen content and res-
piratory gas analysis were performed during the last minute 
of each stage and during the minute before exercise ter-
mination. The plateau in V02 and a disproportionate in-
crease in VC02 were used to define maximal exercise ca-
pacity and the onset of anaerobic metabolism. 
Patients were allowed to rest in the supine position. After 
baseline conditions were reestablished and homeostasis was 
again assured, an initial dose of enalapril, 2.5 mg orally, 
was given and hemodynamic measurements were obtained 
hourly. If an excessive decrease in systolic blood pressure 
(defined as >20 mm Hg from baseline or to an absolute 
level <90 mm Hg) did not occur or if hemodynamic benefit 
(defined as a 25% increase in cardiac output or a 25% 
decrease in pulmonary capillary wedge pressure within 8 
hours) was not observed, a 5 mg dose was administered. 
Hemodynamic measurements were repeated hourly for 12 
hours. If hemodynamic benefit was still not observed, a \0 
mg oral dose of enalapril was given and hourly hemody-
namic measurements were obtained for 12 hours. If hemo-
dynamic benefit did occur with the 5 mg dose, then 5 mg 
was again administered after 12 hours. 
Four to 6 hours after the third enalapril dose (5 mg in 
seven patients and \0 mg in three patients), the patients 
were again placed on the upright bicycle ergometer. Hemo-
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dynamic measurements and respiratory gas analyses were 
determined as just described. 
Open-label dose titration in the remaining J 3 patients 
was accomplished by determining the blood pressure re-
sponse to a 5 mg dose of enalapril. If an excessive decrease 
in blood pressure did not occur (defined previously), patients 
were given a 10 mg dose; if significant hypotension devel-
oped, the dose of enalapril was decreased. 
Long-term controlled trial. This phase consisted of a 
parallel design double-blind study, and 23 patients were 
randomized to either active treatment or placebo for a 12 
week period. The initial dosage of the study dmg was de-
termined from the open-label dose titration just described. 
The drug was administered every 12 hours. Patients under-
went a clinical evaluation with assessment of functional 
status by the questionnaire described previously every 2 
weeks. Functional improvement or deterioration was graded 
as minor, moderate or major. Exercise tolerance tests were 
repeated at the 2, 6 and 12 week visits. Radionuclide ven-
triculography was repeated at the 4th and 12th weeks of 
follow-up. Adjustments in the dosage of diuretic drugs or 
the investigational drug were made at the discretion of the 
physician according to the patient's clinical evaluation. 
Statistical analysis. Values are expressed as the mean 
± SO. Hemodynamic and respiratory changes during the 
acute phase of this investigation were assessed by analysis 
of variance for repeated measures with trend analysis. The 
paired Student's t test was used to analyze the difference 
between two means when the analysis of variance indicated 
that there was a significant difference. Comparison of the 
baseline values between the placebo and enalapril groups 
employed the unpaired t test. Correlations were performed 
using the Pearson product moment analysis for linear re-
Table 1. Effect of Enalapril on Hemodynamic Measurements and Oxygen Consumption at Rest and During Incremental Exercise in 
10 Patients 
Rest Stage I Maximal 
Control Enalapril Control Enalapril Control Enalapril 
HR (beats/min) 93 ± 18 84 ± 9 105 ± 19 105 ± 17 125 ± 26 133 ± 26 
BP (mm Hg) 91 ± 8 79 ± lit 101 ± 9 92 ± 13* 105 ± II 102 ± 13 
CI (liters/min per m2) 1.7 ± 0.3 2.0 ± 0.5 2.5 ± 0.6 3.0 ± 1.1 * 3.5 ± 1.5 4.9 ± 1.8:1: 
SVI (ml/m2) 19.2 ± 5.3 24.4 ± 8.1 t 24.7 ± 8.1 29.8 ± 13.1 * 29.0 ± 11.5 37.8 ± 10.5:1: 
PAP (mm Hg) 31 ± 15 22 ± 10 40 ± 17 33 ± 15 47 ± 18 43 ± 17 
PCWP (mm Hg) 18 ± 13 12 ± 9 25 ± IS 17 ± 13 30 ± 17 24 ± 17 
RAP (mm Hg) 5 ± 4 3 ± 3 9 ± 6 8 ± 6 13 ± 9 9 ± 8 
SVR (dynes·s-cm 5) 2,307 ± 859 1,804 ± 702* 1,839 ± 739 1,434 ± 616t 1,473 ± 751 958 ± 367t 
V02 (mllkg per min) 3.5 ± 0.5 3.5 ± 0.4 6.5 ± 1.1 7.4 ± 1.4 11.2 ± 4.4 15.3 ± 5.6:1: 
A-VOz difference (mlllOO ml) 8.1 ± 2.0 7.3 ± I.7t 10.5 ± 2.4 10.6 ± 3.2 12.8 ± 2.7 12.6 ± 2.3 
Significant differences between control and enalapril are indicated as: *p < 0.05: tp < 0.01: :j:p < 0.001. Values are expressed as the mean ± SO. 
A-V02 difference = arterial-venous oxygen content difference; BP = mean blood pressure; CI = cardiac index; HR = heart rate; PAP = pulmonary 
artery mean pressure; PCWP = pulmonary capillary wedge pressure: RAP = right atrial pressure: SVI = stroke volume index: SVR = systemic vascular 
resistance; VOz = oxygen consumption. 
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lations. The chi-square test was used to compare changes 
in functional status between the treated and placebo groups. 
Statistical significance is defined as p < 0.05. 
Results 
Rest hemodynamic response to enalapril (Table 1, 
Fig. 1 and 2). Enalapril caused a 13.0% decrease in mean 
blood pressure (p < 0.01). The systemic vascular resistance 
decreased 20% (p < 0.05). At rest, oxygen consumption 
was not altered by enalapril but the arterial-venous oxygen 
content difference narrowed (p < 0.01). The change in 
cardiac index did not achieve statistical significance because 
the heart rate decreased in six subjects. Stroke volume index, 
however, increased 21 % (p < 0.01). Pulmonary artery mean 
pressure, pulmonary capillary wedge and right atrial pres-
sures did not decrease significantly though trends suggesting 
a decrease in cardiac filling pressures were apparent. 
Effect of enalapril on exercise hemodynamics (Table 
1, Fig. 1 and 2). The decrease in mean blood pressure after 
enalapril observed at rest persisted through stage 1 and sub-
maximal exercise (each p < 0.05). Stroke volume index 
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Figure 1. Effect of enalapril on upright 
blood pressure (BP), cardiac index (CI) 
and systemic vascular resistance (SVR) at 
rest and during exercise. Exercise stages 
are defined in the text. Values are ex-
pressed as the mean ± SD. Submax = 
submaximal. 
was augmented by the converting enzyme inhibitor during 
stage I (p < 0.05) and maximal exercise (p < 0.001). 
Before enalapril administration, incremental exercise caused 
a progressive decrease in systemic vascular resistance. After 
treatment, the systemic vascular resistance decreased further 
during stage I and maximal exercise (each p < 0.01). Al-
though trends are suggested, enalapril caused no significant 
\ decrease in pulmonary capillary wedge or right atrial pres-
sure during exercise. 
Effect of enalapril on oxygen consumption and ex-
ercise capacity (Fig. 3). Enalapril increased the exercise 
duration in 8 of the 10 patients. For the group, exercise 
duration increased from 9. 1 ± 1. 7 to 10.6 ± 2.5 minutes 
(p < 0.05). By design, the work loads at stage 1 and sub-
maximal exercise were similar before and after enalapril 
treatment. Therefore, measured oxygen consumption for 
these stages was comparable despite drug intervention. Con-
sistent with the increase in exercise tolerance, maximal ox-
ygen consumption increased in 9 of the 10 patients. The 
average maximal oxygen consumption increased from 11.2 
± 4.4 to 15.3 ± 5.6 mllkg per min (p < 0.001). Compared 
with pretreatment values, there was no change in the arterial-
SWI r (g.m/M2) 
/ 
/ 
/ 
J/ Figure 2. Effect of enalapril on upright 
I// heart rate (HR), stroke volume index (SVI) and stroke work index (SWI) at 
/ rest and during exercise. Values are ex-
pressed as the mean ± SD. 
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Figure 3. Effect of enalapril on exercise duration and maximal 
oxygen consumption (V02). Values are expressed for individual 
patients as well as the mean ± SD for the group. 
venous oxygen difference during any stage of exercise after 
enalapril. The respiratory quotient at maximal exercise 
was 1.2 ± 0.2 before treatment and 1.1 ± 0.1 after treat-
ment (p = NS), consistent with the onset of anaerobic 
metabolism. 
Plasma renin activity. Pretreatment supine plasma renin 
activity ranged from 1 to 42 ng/ml per h (average 6.9 ± 
13.3). During upright posture before exercise, plasma renin 
activity increased to 10.6 ± 14.7 ng/ml per h (p < 0.02), 
and at peak exercise, it increased further to 16.8 ± 2l.3 
ng/ml per h (p < 0.01). After enalapril treatment, the supine 
plasma renin activity increased in eight of nine patients to 
13.6 ± 13.4 ng/ml per h (p = NS). During upright rest, 
Table 2. Baseline Characteristics of Study Population of 
23 Patients 
Placebo Enalapril 
Number 12 II 
Sex 
Male 12 II 
Female 0 0 
Age (yr) 59.8 ± 7.9 53.6 ± 12.8 
Weight (kg) 77±1O 78 ± II 
Cause of CHF 
Primary cardiomyopathy 2 4 
Coronary artery disease 9 3 
Hypertension 2 
End-stage valvular disease 0 2 
Duration of CHF (yr) 2.7 ± 2.9 1.5 ± 1.6 
NYHA classification 2.8 ± 0.5 2.6 ± 0.5 
LVEF(%) 26.8 ± 9.2 25.3 ± 8.7 
ETT (min) lOA ± 3.8 11.5 ± 2.6 
Values are expressed as the mean ± SO. CHF = congestive heart 
failure; ETT = exercise tolerance time; L VEF = left ventricular ejection 
fraction; NYHA = New York Heart Association. There were no significant 
differences between the placebo and enalapril groups for any of the baseline 
variables. 
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plasma renin activity increased in 8 of 10 patients and av-
eraged 19.7 ± 14.1 ng/ml per h; at peak exercise, it av-
eraged 28.9 ± 20.5 ng/ml per h (p < 0.01 versus rest 
values). 
Long-term follow-up evaluation. Eleven patients were 
assigned to active treatment, and 12 patients to placebo. 
There were no statistically significant differences between 
the two groups in baseline clinical characteristics or pre-
treatment exercise tolerance or left ventricular ejection frac-
tion (Table 2). 
Each of the 11 patients assigned to active treatment with 
enalapril completed the 12 week follow-up period. Their 
average weight was 78 ± 11 kg initially and did not change 
significantly during the follow-up period. Similarly, the weight 
of the 12 patients assigned to placebo treatment was 77 ± 
10 kg initially and did not change significantly during the 
follow-up period. In the enalapril group, the initial daily 
dose of enalapril was 10 mg in five patients and 20 mg in 
six. At the end of the follow-up period, the dose had been 
increased in five patients so that four patients were receiving 
10 mg, three receiving 20 mg and four receiving 40 mg. In 
the placebo group, the initial daily dose of placebo was 5 
mg in one patient, 10 mg in four patients and 20 mg in 
seven patients. Among those who completed the follow-up 
period, the daily dose of placebo was increased in six such 
that one patient was receiving 5 mg, one 10 mg, one 20 
mg and six 40 mg daily. The diuretic dose in the enalapril 
group was decreased in six patients, unchanged in four and 
increased in one patient; in the placebo group, it was de-
creased in three patients, unchanged in eight and increased 
in one patient. 
Functional improvement. By the end of this period, 73% 
of the patients randomized to enalapril considered them-
selves improved. Three patients (27%) thought there had 
been no change, and no patient's condition deteriorated. Of 
the 12 patients assigned to placebo, 3 did not complete the 
12 week follow-up period. One complained of nausea and 
one developed pulmonary edema; in each case, the code 
was broken. The third patient underwent elective abdominal 
surgery and withdrew from the protocol. By the final eval-
uation, 25% of the placebo-treated patients considered them-
selves improved and 25% thought their symptoms had de-
teriorated. The difference in the clinical response between 
enalapril and placebo groups was statistically significant (p 
< 0.02). 
Of the patients assigned to active treatment, seven were 
initially in functional class III and four in class II. Four 
patients improved their functional classification during the 
follow-up period. Of the patients assigned to placebo treat-
ment, nine were initially in class III and three in class II. 
None of these patients improved their functional classifi-
cation, and in two patients it deteriorated. 
Exercise capacity (Fig. 4). There was no significant 
difference in the baseline exercise capacity of those patients 
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Figure 4. Effect of enalapril and placebo on exercise capacity 
during two baseline treadmill tests and during the 12 week con-
trolled trial (Follow-Up). Values are expressed as the mean ± 
SO. *p < 0.05, enalapril versus baseline; **p < 0.01, enalapril 
versus baseline; ***p < 0.001, enalapril versus baseline; tp < 
0.05, enalapril versus placebo. 
assigned to placebo compared with those assigned to active 
treatment. The baseline treadmill time in the placebo group 
was 10.4 ± 3.8 minutes and did not increase significantly 
during subsequent tests. In the enalapril group, treadmill 
time was 11.6 ± 2.7 minutes at baseline and was signifi-
cantly increased at 2 (12.9 ± 2.5 minutes), 6 (13.0 ± 3.1 
minutes) and 12 weeks (13.6 ± 3.6 minutes). 
Ejection fraction. The baseline radionuclide ejection 
fraction was similar in the placebo and enalapril groups 
(26.8 ± 9.2 versus 25.3 ± 8.7%, P = NS). Ejection 
fraction obtained in the placebo-treated patients during the 
4th (28.5 ± 12.9%) and 12th weeks (29.6 ± 11.8%) of 
follow-up was not statistically different from the baseline 
period. Similarly, in the enalapril-treated patients, ejection 
fraction determined at the 4th (26.7 ± 10.3%) and 12th 
week (29.0 ± 12.8%) visits was not significantly increased. 
Adverse effects. One patient developed symptomatic 
hypotension and one transient azotemia during the dose 
titration phase; in these individuals, the dosage of enalapril 
was decreased but the study was continued. Of those patients 
assigned to active treatment with enalapril, no significant 
adverse effects occurred during the blinded follow-up phase. 
No patients developed symptomatic hypotension, skin rash, 
worsening renal function, nephrotic syndrome or hemato-
logic abnormalities. Of those patients assigned to placebo, 
one patient complained of nausea. No patients died during 
the course of this study. 
Discussion 
Hemodynamic response to enalapril at rest. The im-
provement in cardiac function at rest observed after the 
administration of enalapril in this investigation is similar to 
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that reported previously with teprotide, captopril and en a-
lapril (1-8,14,15). Blood pressure and systemic vascular 
resistance decreased and stroke volume increased. No sig-
nificant decrease in pulmonary capillary wedge or right atrial 
pressure occurred, although a trend suggesting a decrease 
in cardiac filling pressures was evident. The apparent ab-
sence of effect on filling pressures may be secondary to an 
insufficient number of patients and lack of statistical power. 
Exercise hemodynamic changes after enalapril. 
Improvement in cardiac function during exercise occurred 
after enalapril administration. Stroke volume was aug-
mented beyond pretreatment values during submaximal and 
maximal exercise, and the cardiac output was enhanced 
during maximal exercise. Since enalapril did not alter the 
heart rate, the increase in cardiac output is attributed solely 
to an increase in stroke volume. Because enalapril has no 
known positive inotropic properties, the increase in stroke 
volume presumably is a consequence of systemic vasodi-
lation. This vasodilation may have occurred in nonexercis-
ing tissues. In patients with heart failure, converting enzyme 
inhibition does not have a uniform effect on each regional 
circulation (21). At rest, renal vasodilation is dispropor-
tionate to the negligible changes in limb, coronary or 
splanchnic resistance (22,23). During exercise, a further 
decrease in systemic vascular resistance after enalapril may 
be secondary to additional vasodilation in nonexercising 
tissue. Alternatively, even during maximal exercise, when 
autoregulatory phenomena are primarily responsible for va-
sodilation in exercising limbs, enalapril may have caused a 
further decrease in leg vascular resistance. The latter ex-
planation would contrast with observations by Kugler et al. 
(9) who inferred that captopril does not increase blood flow 
in the exercising limb because no change occurred in femoral 
vein oxygen content. 
Acute effect on exercise capacity. Eight of 10 patients 
prolonged their exercise time acutely after enalapril treat-
ment. Consistent with the longer exercise duration, maximal 
oxygen consumption increased. Acute improvement in ex-
ercise duration with augmented oxygen consumption sub-
sequent to enalapril contrasts with the absence of the changes 
after captopril treatment (9,10). Though there are several 
exceptions, most studies with vasodilators in patients with 
heart failure have not found an acute improvement in ex-
ercise capacity (24-29). Since this phase of the investigation 
was not blinded, investigator or patient bias could have 
caused sufficient enthusiasm to prolong the exercise duration. 
Correlation with plasma renin activity. The hemo-
dynamic changes after enalapril administration in this in-
vestigation are most likely the result of a decrease in the 
concentration of angiotensin II. In most of our patients, the 
plasma renin activity determined at rest and during exercise 
was higher after treatment, consistent with a loss of negative 
feedback inhibition. As with other converting enzyme in-
hibitors, changes in concentrations of bradykinin and pros-
JACC Vol. 6, No.1 
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taglandins may contribute to the vasodilation (30-32). Fur-
thermore, interaction of the renin-angiotensin system with 
the sympathetic nervous system may be pertinent to ob-
served hemodynamic changes. For example, a decrease in 
sympathetic nervous system activity during exercise either 
directly or as a reflex adjustment to improved cardiac func-
tion may potentiate the vasodilator effect of angiotensin 
inhibition. 
Clinical efficacy of enalapril. The results of the follow-
up phase of this study demonstrate the clinical efficacy of 
enalapril as compared with placebo in patients with conges-
tive heart failure. Subjectively, 73% of patients assigned to 
enalapril thought their functional capacity had improved 
compared with 25% of patients assigned to placebo. Ob-
jectively, exercise duration increased in those patients taking 
the converting enzyme inhibitor, but not in those taking 
placebo. The findings of this investigation are comparable 
with those reported with captopril (10,11) and are consistent 
with a report by Sharpe et al. (33). In contrast, the evidence 
for long-term effectiveness of other vasodilators, such as 
hydralazine and prazosin, is conflicting, perhaps because 
tolerance to those drugs develops (29,34-37). 
Unlike the acute observations, the improvement in ex-
ercise capacity during long-term treatment cannot be attrib-
uted to greater familiarity with the treadmill protocol or to 
investigator bias. Patients underwent at least two treadmill 
tests during the baseline period to assure the stability of the 
measurement. Furthermore, the patients assigned to placebo 
were tested as many times during the 12 week follow-up 
phase as those assigned to enalapril, but did not increase 
their exercise capacity. Investigator bias is excluded because 
of the blinded nature of the protocol. 
The clinical improvement that occurred in the patients 
randomized to enalapril cannot be explained by alterations 
in concomitant drug therapy. In fact, diuretic dosages were 
decreased in 6 of the 11 patients taking enalapril and in-
creased in only one; whereas, in patients randomized to 
placebo, diuretic dosages were decreased in only 3 of the 
12 patients. 
Side effects. No adverse effects that can be attributed 
to enalapril occurred during the long-term follow-up phase. 
During the dose titration phase, one patient developed symp-
tomatic hypotension, and one patient had transient azotemia; 
in these individuals the dosage had to be decreased. There 
were no incidents of skin rash, dysgeusia, proteinuria, azo-
temia or hematologic abnormalities in those patients ran-
domized to active drug during the 12 week maintenance 
period. Each of the three patients withdrawn from the study 
was taking placebo. A larger group of treated patients, how-
ever, would be required to confidently determine the inci-
dence of side effects. 
Conclusion. In patients with congestive heart failure, 
enalapril improves cardiac function at rest and during ex-
ercise. As opposed to most observations with other vaso-
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dilators, both exercise duration and maximal oxygen con-
sumption increased after acute administration of the drug. 
When compared with placebo, maintenance therapy with 
enalapril resulted in symptomatic improvement and in-
creased exercise capacity. If experience with large numbers 
of patients confirms a low incidence of significant adverse 
effects, enalapril should be a valuable form of therapy for 
patients with congestive heart failure. 
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